Allakos halts AK006 development after phase 1 trial disappoints. Restructuring includes workforce cuts and $34 million-$38 ...

Allakos, Inc. shares lost more than three-quarters of its market capitalization on Tuesday afternoon, marking a record low ...

Purpose: The pharmacology, efficacy, dosage, adverse events, and economics of omalizumab are discussed. Summary: Omalizumab, a recombinant DNA-derived humanized monoclonal antibody, binds to the ...

Allakos (ALLK) announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria. In the CSU cohort, 34 adult ...

Shares of Allakos (ALLK) are down 75% in pre-market trading after the company announced it will discontinue further clinical development of ...

Objectives: To describe allergic asthma and allergic rhinitis pathophysiology and review the pharmacologic, pharmacokinetic, pharmacodynamic, efficacy, and safety data for omalizumab. Methods ...